Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Van Cutsem, E.
Right arrow Articles by Osterwalder, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Cutsem, E.
Right arrow Articles by Osterwalder, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:484-485, 2002
© 2002 European Society for Medical Oncology

Letters to the Editor

Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil

E. Van Cutsem1, P. M. Hoff2, J. L. Blum3, M. Abt4 and B. Osterwalder5

1University Hospital Gasthuisberg, Leuven, Belgium (E-mail: eric.vancutsem@uz.kuleuven.ac.be); 2Centro Paulista de Oncologia, Albert Einstein Hospital, Sâo Paulo, Brazil; 3Baylor-Charles A. Sammons Cancer Center, US Oncology, Dallas, Texas, USA; 4Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 5Clinical Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland (E-mail: eric.vancutsem@uz.kuleuven.ac.be)

Acute cardiotoxicity has recently been reported in two patients receiving capecitabine [1, 2], an oral fluoropyrimidine that undergoes a three-step enzymatic conversion to 5-fluorouracil (5-FU). Cardiotoxicity due to 5-FU is a rare but serious side effect, reported in 1–18% of patients [3]. The most common symptom of . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Coward, N. Maisey, and D. Cunningham
The effects of capecitabine in Raynaud's disease: a case report
Ann. Onc., May 1, 2005; 16(5): 835 - 836.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Sudhoff, M.-D. Enderle, M. Pahlke, C. Petz, C. Teschendorf, U. Graeven, and W. Schmiegel
5-Fluorouracil induces arterial vasocontractions
Ann. Onc., April 1, 2004; 15(4): 661 - 664.
[Abstract] [Full Text] [PDF]